IDH2 expression correlated with HBsAg (P =0.015), AFP (P <0.001), and tumor differentiation (P =0.015) (Additional file 2: Table S2). Other clinical characteristics were not directly related to the expression of 5-hmC or IDH2. Salubrinal in vitro Table 1 Summary of the correlations of 5-hmC and IDH2 protein expression with clinicopathological features in the training cohort (N = 318) Clinicopathological indexes   No. of patients No. of patients   5-hmC Low 5-hmC High P† IDH2

Low IDH2 High P† Sex Female 18 36 0.007 28 26 0.765   Male 141 123   131 133   Age(year) ≤50 55 65 0.247 60 60 1.000   >50 104 94   99 99   HBsAg Negative 30 26 0.556 28 28 1.000   Positive 129 133   131 131   HCV Negative 158 158 1.000 157 159 0.156   Positive 1 1   2 0   AFP ≤20 83 37 <0.001 58 62 0.644   >20 76 122   101 97 GSK1904529A   γ-GT(U/L) ≤54 87 81 0.500 78 90 0.178   >54 72 78   81 69   Liver cirrhosis No 32 26 0.384 23 35 0.081   Yes 127 133   136 124   Tumor number Single 131 134 0.652 134 131 0.652   Multiple 28 25   25 28   Tumor size(cm) ≤5 97 108 0.197 99 106 0.412   >5 62 51   60 53   Tumor encapsulation Complete 94 88 0.496 93 89 0.650   None

65 71   66 70   Microvascular invasion Absent 113 107 0.466 106 114 0.331   selleck compound Present 46 52   53 45   Tumor differentiation I + II 129 115 0.063 113 131 0.017   III + IV 30 44   46 28   TNM stage I 98 93 0.567 93 98 0.567   II + III 61 66   66 61   Abbreviations: HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; γ-GT, γ-glutamyl

transferase; TNM, tumor-node-metastasis. †A P-value < 0.05 was considered statistically significant. P-values were calculated using the Pearson chi-square test. Boldface type indicates significant values. Association between combined 5-hmC and IDH2 expression and outcome in the training cohort By the last mafosfamide follow-up in the training cohort (November 2011), 47.2% (150/318) of the patients had suffered a recurrence and 36.5% (116/318) had died. The 1-, 3-, and 5-year OS rates in the cohort were 83.6%, 67.6%, and 63.5% and the cumulative recurrence rates were 32.7%, 46.9%, and 52.8%, respectively. Additionally, we found that the 1-, 3-, and 5-year survival rates of the 5-hmC High patients were significantly higher than those of the 5-hmC Low group (87.4% vs. 79.9%, 77.4% vs. 57.9%, and 73.0% vs. 54.1%, respectively) (Figure 2a). Similarly, the 5-hmC Low patients had a poorer prognosis at 1, 3, and 5 years, with higher cumulative recurrence rates than the 5-hmC High patients (40.3% vs. 25.2%, 56.6% vs. 37.1%, and 61.6% vs. 44.0%, respectively) (Figure 2b). We also discovered that the 1-, 3-, and 5-year survival rates of the IDH2 High patients were significantly higher than those of the IDH2 Low group (93.7% vs. 73.6%, 76.7% vs. 58.5%, and 71.7% vs. 55.3%, respectively) (Figure 2a).